Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.

Through the acquisition, Studsvik expands its capacity for development of technology-agnostic SMR projects and extends its role to developing new nuclear power projects. The founders of Kärnfull Next will join the executive team as Studsvik builds a platform for full-lifecycle nuclear services.

The transaction is subject to customary regulatory approvals.

Vinge's team consisted primarily of Matthias Pannier, Peter Sundgren, Edvard Gustafsson and Ida Appelgren (M&A), Rikard Lindahl and Maximilian Bengtsson (Capital Markets and Public M&A), Johan Cederblad and Stina Larsson (Permits and Environment), Wilma Hellman (Real Estate), Malin Ohlin and Christoffer Nordin (Corporate Commercial), Nicklas Thorgerzon (IT and GDPR), Daniel Wendelsson and Hilda Ivarsson (FDI), Emma Gustavsson and Alex Öberg (IP), Simon Söderholm and Ida Pettersson (Employment), Gabriel Chabo (Banking and Finance) and Jasmina Skandrani (Transaction Support).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026